Results

CRUZIVAX publication

Ramponi F., Aerts C., Sartor P., Pinazo M.J., Freilij H., Guzmán C.A., ... , Malchiodi E., Sicuri E. (2022)
Development of vaccines for Chagas disease (CRUZIVAX): stakeholders' preferences and potential impacts on healthcare
Gaceta Sanit., 37
DOI: 10.1016/j.gaceta.2022.102275 HZI-Repositorium PubMed

This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs.

CRUZIVAX public deliverables

  • D16.1: A PowerPoint presentation of the project
    pdf (1.80 MB)
  • D16.2: A PowerPoint presentation of the Cruzivax project website
    pdf (4.36 MB)

When available, further results will be made public here and on our Zenodo Community.
https://zenodo.org/communities/cruzivax/